



Stereotaxis to Present at Cantor Fitzgerald Inaugural Healthcare Conference in New York on July 8, 2015

July 2, 2015

ST. LOUIS, July 2, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills, CEO, and Martin C. Stammer, CFO, will present at the Cantor Fitzgerald Inaugural Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m. Eastern Time. The conference is being held at Le Parker Meridien Hotel in New York City.

To arrange a one-on-one meeting with Stereotaxis management, please contact either your Cantor Fitzgerald sales person or the MKR Group, Stereotaxis' investor relations firm, at stxs@mkr-group.com.

Conference Details

- Cantor Fitzgerald Inaugural Healthcare Conference
- July 8, 2015
- Le Parker Meridien Hotel in New York City
- More information can be found at: <http://www.cantorconferences.com>

Cantor Fitzgerald's Inaugural Healthcare Conference is a one-day, multi-track conference featuring presentations from 50+ top tier healthcare companies across the broad continuum of healthcare. From "bench to bedside", the conference aims to connect leading public and private healthcare companies with institutional investors, addressing investment opportunities and trends shaping healthcare from the earliest stage of development ("bench") to patient treatment ("bedside").

The conference agenda includes presentations from C-suite executives representing a variety of healthcare subsectors including biotechnology, specialty pharmaceuticals, medical technology, life science tools and diagnostics, and healthcare facilities and services in a variety of formats, as well as highly relevant topic panels.

The one-day conference aims to provide investors with broad access to leading healthcare companies and an ability to drill down into some of the most relevant topics in healthcare today. With over 50 publicly traded companies and numerous private companies available throughout the day, investors will have the opportunity to expand knowledge and sharpen investment focus and participate in one-on-one meetings with company management.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core *Epoch*® Solution includes the *Niobe*® magnetic navigation system, the *Odyssey*® portfolio of lab optimization, networking and patient information management solutions, and the *Vdrive*® robotic navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan, and elsewhere. The *V-Loop*™ variable loop catheter manipulator, the *V-CAS*™ catheter advancement system, and the *V-Sono*™ ICE catheter manipulator including *Vmotion* automation features have received clearance in the U.S. and European Union. For more information, please visit www.stereotaxis.com.

CONTACT: Press Contact:

Martin Stammer
Chief Financial Officer
314-678-6155

Investor Contact:

Todd Kehrlí / Jim Byers
MKR Group, Inc.
323-468-2300

[Stereotaxis logo](#)

Stereotaxis, Inc.